RxDoctor Payments Data

James O Keefe, MD

Nuclear Cardiology · Kansas City, MONPI 1134187339

Payments from drug & device makers

$496,004in general payments, 2019–2025

Across 439 payments — averaging $1129.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$155K
  • Amgen$107K
  • Lilly USA, LLC$88K
  • Johnson & Johnson$56K
  • AstraZeneca$40K
  • Sanofi-aventis U.S. LLC$20K
  • plus $30K from 5 others

What the payments were for

  • Consulting fees$18,7404%
  • Speaking & faculty fees$435,84788%
  • Travel & lodging$34,1797%
  • Food & beverage$7,2021%
  • Education$360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim131$155,219
Amgen115$106,943
Lilly USA, LLC59$87,613
Johnson & Johnson40$56,456
AstraZeneca43$39,526
Sanofi-aventis U.S. LLC25$20,187
Eli Lilly6$18,900
Regeneron Healthcare Solutions, Inc.15$5,187
Bayer3$2,864
Regeneron1$2,660
Novartis1$448

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few nuclear cardiology providers in Missourito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$128,794
Medicare patients
1,221
Services billed
2,918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab710$840,135
JardianceEmpagliflozin398$459,154
EliquisApixaban315$333,854
Praluent PenAlirocumab215$259,655
OzempicSemaglutide174$250,013
XareltoRivaroxaban87$109,761
MounjaroTirzepatide90$105,940
EntrestoSacubitril/Valsartan35$52,502
WegovySemaglutide32$46,218
FarxigaDapagliflozin Propanediol39$39,154
Ezetimibe943$20,625
LivaloPitavastatin Calcium31$15,887
Repatha SyringeEvolocumab16$14,459
VascepaIcosapent Ethyl23$10,578
Carvedilol ErCarvedilol Phosphate20$7,929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$155,219$459,154398 claims
Johnson & JohnsonXarelto$56,456$109,76187 claims
Lilly USA, LLCMounjaro$87,613$105,94090 claims
NovartisEntresto$448$52,50235 claims
AstraZenecaFarxiga$39,526$39,15439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nuclear cardiology providers in Missourion file to place this against a meaningful peer group, so we don't.

Other nuclear cardiology in Kansas City

Where these figures come from

Is this you, or does something look wrong? →